OraQuick® HCV Rapid Antibody Test - not proceeding

A single use, point-of-care test for the qualitative detection of antibodies to hepatitis C virus (HCV) in oral fluid, fingerstick whole blood, venipuncture whole blood, plasma and serum. If you wish to be alerted to developments regarding this technology, including consultations and the release of NICE guidance, please express your interest by send an e-mail to medtech@nice.org.uk for the attention of the topic project manager.
 
Status
Suspended
Publication date
TBC
Notification Date
October 2010

Provisional Schedule

Submission Date: TBC
Topic Selection: 16 December 2010
Draft guidance meeting TBC
Consultation opens: TBC
Consultation ends: TBC
Final guidance meeting: TBC

Project Team

Patient Involvement Lead: Laura Norburn
Analyst: Sarah Baggaley
Communications Lead: Tonya Gillis
Project manager: Marlon Hope
Implementation Lead: Katie Worrall

Stakeholders

  • To be confirmed

Timeline

Date
Update
5 August 2011
NICE's assessment of this medical technology is suspended.
29 June 2011
NICE is unable to develop medical technology guidance on OraQuick HCV Rapid Antibody Test because the manufacturer has decided not to pursue a submission for evaluation to the Medical Technologies Evaluation Programme (MTEP). NICE will therefore not be developing guidance on this topic.
Get involved